Objective: Vascular Ehlers-Danlos syndrome (vEDS) is a rare disorder and 1 of 13 types of EDS. The syndrome results in aortic and arterial aneurysms and dissections at a young age. Diagnosis is confirmed with molecular testing via skin biopsy or genetic testing for COL3A1 pathogenic variants. We describe a multi-institutional experience in the diagnosis of vEDS from 2000 to 2015.
The Ehlers-Danlos syndromes (EDS) are a group of 13 heritable connective tissue disorders generally characterized by joint hypermobility, skin hyperextensibility, and tissue fragility. 1 Vascular EDS (vEDS), previously called EDS type IV, is one of the subtypes with an estimated frequency of 1 in 50,000 and accounts for 5% of all EDS cases. 2, 3 The syndrome results from heterozygous mutations in the COL3A1, which encodes type III collagen. 4 The effect of the pathogenic COL3A1 variants includes the production of defective type III collagen or the reduction in the quantity of type III collagen. The clinical manifestations include spontaneous arterial dissections, aneurysms, and rupture at a young age. Additionally, affected individuals are at increased risk for spontaneous intestinal perforation and pregnancy-related uterine rupture. 2, 5, 6 Consequently, individuals with vEDS have been reported to have an average life expectancy of less than 50 years with mortality usually related to arterial rupture or complications related to arterial repairs in these circumstances. 2, 7 Establishing the diagnosis in vEDS is challenging owing to its rarity and heterogeneous clinical presentation. 8, 9 The diagnosis is suspected based on clinical findings and confirmed by molecular resting. Molecular testing includes biochemical testing via a skin biopsy and genetic testing for pathogenic COL3A1 variants (the latter is the predominant contemporary mode of diagnosis). 1, 2 We describe a multi-institutional experience in the diagnosis of vEDS and compare the demographics and clinical characteristics of individuals diagnosed using clinical diagnostic criteria only and those in whom the diagnosis was confirmed via molecular testing.
METHODS
This is a multi-institutional retrospective cohort study of individuals diagnosed with vEDS between January 1, 2000, and December 31, 2015. The institutions were recruited through the Vascular Low Frequency Disease Consortium (University of California-Los Angeles Division of Vascular Surgery). 10 A call for participation to institutions was sent through electronic mail. Each participating center obtained institutional review board approval from their home institution. The institutional review boards waived the patient consent process owing to minimal patient risk. Data were collected by each institution's respective investigator(s), transmitted in a deidentified fashion to the University of Washington, and stored using a password-encrypted database maintained by the University of Washington.
Individuals were identified with International Classification of Diseases (ICD)-9-CM code 756.83 or ICD-10-CM code Q79.6 for EDS as coded in the electronic medical records. This diagnostic code includes vEDS and an additional 12 subtypes of EDS. 1 A review of these case records was then performed to select individuals with vEDS based on the documentations in the medical records by providers caring for the patients. Individuals with the other 12 forms of EDS were excluded. Data regarding demographics, current age, age at diagnosis, and family history (defined as a family history of vEDS, aortic or arterial aneurysms and dissections, and/or sudden death) were abstracted.
The major and minor clinical diagnostic criteria for the cohort were reviewed. The major diagnostic criteria for vEDS include arterial rupture, intestinal rupture, uterine rupture during pregnancy, and family history of vEDS. 1, 11 All arterial events (defined as aortic/arterial aneurysm, pseudoaneurysm, dissection, fistula, or rupture) were reviewed and noted. The minor diagnostic criteria include the following 1,11 :
d Hypermobility of small joints. d Easy bruising that occurs spontaneously or with minimal trauma. d Thin translucent skin that is especially noticeable on the chest and abdomen. d Characteristic facial appearance, 8 Method of vEDS diagnosis was also reviewed. This review included whether the diagnosis was made clinically without molecular confirmation or a diagnosis that included molecular confirmation, namely, biochemical testing of a skin biopsy confirming disruption of the type III collagen fibrils, and genetic testing for pathogenic mutations in COL3A1. Genetic testing results including the COL3A1 variant and protein effect were reviewed by a single geneticist (P.H.B.) and classified for pathogenicity. COL3A1 variants were considered pathogenic (causative) if they met any of the following criteria in keeping with the American College of Medical Genetics guidelines 3, 7, 12 :
-The variant resulted in substitution for a glycine residue in the Gly-X-Y repeats of the triple helical domain, thus disrupting the type III collagen folding process and leading to production of a minimal amount of normal collagen. This type of mutation is called a missense mutation and is the most common type of mutation affecting COL3A1. -The variant altered the canonical splice acceptor site (-1G, -2A) or donor site (þ1G, þ2T). This type of mutation can lead to exon skip and splice site mutations by creating a frameshift that result in exon(s) deletion leading to defective collagen production similar to missense mutations. -The variant creates premature termination codon either directly or through a frameshift mutation. This type of mutation leads to a haploinsufficiency mutations (null mutation) and results in production of one-half the normal amount of type III collagen. The individuals affected by this type of mutation present at a later age and have milder arterial disease than those who have the missense or exon skipping mutations.
Variants were considered nonpathogenic if they created amino acid substitutions in the amino-terminal propeptide or altered X-or Y-position amino acids in the triple helical domain and as such are not pathogenic. 3, 5, 13 Individuals were classified into two cohorts: pathogenic COL3A1 variants cohort and clinical diagnosis only cohort (no molecular confirmation). The demographics, major and minor diagnostic criteria, and arterial events between in the two cohorts were compared. Age results are presented as means and standard deviation. Age means were compared in the two cohorts using the Student t-test. Categorical data, including sex, presence of specific comorbidities, and diagnostic criteria, were compared between the two cohorts using the Pearson c 2 test. The comparison of all-cause mortality was performed using a Kaplan-Meier survival curve with log-rank test comparison of the curves. The assumptions of Kaplan-Meier analysis were met: the event status is mutually exclusive between censored and mortality, the survival time is precisely measured and recorded, left censoring is not occurring because the starting point of the survival time is clearly defined and recorded, censoring and the event (mortality) are independent, there is no secular trend over time that biases the mortality, and the number and pattern of censoring in the two groups is similar. All statistical tests were two-sided and a P value of less than .05 was considered statistically significant. Statistical analysis was performed using Microsoft Excel 2007 software (Microsoft, Redmond, Wash) and SPSS version 19 for Windows (SPSS, Inc, Chicago, Ill).
RESULTS
A total of 173 individuals (35.3% male, 56.6% Caucasian) were identified by chart review as having a diagnosis of EDS during the study period at 11 institutions: nine in the United States (n ¼ 149) and one each Germany (n ¼ 5) and Italy (n ¼ 19). Nonpathogenic alterations in COL3A1 were found in 11 individuals (9.8%) who underwent genetic testing and as such they did not have vEDS and were excluded from subsequent analysis (Nterminal propeptide amino acid substitutions in the amino-terminal propeptide [n ¼ 3] and altered X-or Yposition amino acids in the triple helical domain [n ¼ 8]). Among the remaining individuals, 86 (47.7% male, 68% Caucasian, 48.8% positive family history) had pathogenic COL3A1 variants (Fig 1) . A diagnosis of vEDS was made by clinical criteria only in 56 individuals (34.5%). An additional 20 individuals (12.3%) were noted to carry the diagnosis of vEDS, but data from the genetic testing were unavailable for review and could not be obtained. A sensitivity analysis was performed and demonstrated substantial differences between this group and the cohort with pathogenic COL3A1 variants; thus, they were included in clinical diagnosis only cohort. were younger at the age of diagnosis compared with those without a family history (21.3 6 13.6 years vs 30.2 6 13.7 years; P ¼ .008). In contrast, among those with a child diagnosed with vEDS (n ¼ 11), the age of diagnosis was significantly older compared with the rest of the cohort (47.4 6 18.8 years vs 26.5 6 14.3 years; P < .001). There was the stepwise age increase with given complications so that spontaneous pneumothorax (n ¼ 12, 66.7% male) occurring at a younger age than spontaneous intestinal perforation (n ¼ 14, 42.3% male) and arterial rupture (n ¼ 15, 33.3% male; Fig 2) .
Comparison of the clinical features between the two cohorts. The clinical diagnosis only cohort had a significantly higher number of females compared with the cohort with pathogenic COL3A1 variants (80.3% vs 52.3%; P < .001) and a significantly higher frequency of mitral valve prolapse (10.5% vs 1.2%; P ¼ .009). There were also differences in the frequency of minor and major clinical diagnostic (Table I) . Among the minor diagnostic criteria, there was a significantly higher frequency of joint hypermobility (68.4% vs 40.7%; P < .001) and a significantly lower frequency of easy bruising (23.7% vs 64%; P < .001) and thin translucent skin (17.1% vs 48.8%; P < .001). In terms of major diagnostic criteria, this cohort had a significantly lower frequency of arterial rupture, intestinal perforation, and spontaneous pneumothorax/ hemothorax (Table I ). The number of arterial events was significantly higher among those with pathogenic COL3A1 variants (Table II) .
Mortality. There were no differences in all-cause mortality (Fig 3) between the cohort with pathogenic COL3A1 variants and the cohort diagnosed without molecular confirmation (Table I ). In the cohort with pathogenic COL3A1 variants, the mean follow-up time from the time of diagnosis was 8.2 6 8.28 years. There were 13 deaths (15.1%) at a mean age of 40.3 6 15.5 years. Causes of death were two strokes, one coronary artery dissection, one ventricular rupture, two artic dissections, one hemothorax, and one mesenteric arterial rupture; in the rest of the cases, the cause was unknown. In the cohort without molecular confirmation, the mean follow-up time from the time of diagnosis was 9.8 6 8.8 years. There were 6 deaths (7.8%) in this group (mean age, 35.8 6 15.6 years). Causes of deaths were noted as a hemorrhagic stroke (n ¼ 1), dissection and rupture without further detail (n ¼ 1), complications from a perforated viscus (n ¼ 1), and unknown (n ¼ 3).
DISCUSSION
Owing to its rarity and heterogeneous presentation, the diagnosis of vEDS can be difficult even for experienced clinicians. This contemporary experience from 11 institutions highlights the challenges related to an accurate diagnosis of vEDS. In this cohort, one-third of the individuals were given the diagnosis of vEDS based on clinical criteria alone without confirmatory molecular testing in the form of skin biopsy or genetic testing for pathogenic variants in COL3A1. The demographics and disease manifestations among this group make it clear that this was a different group than those with pathogenic COL3A1 variants. In fact, their most common features were more consistent with hypermobile EDS or classical EDS than with vEDS (both in which skin hyperextensibility and generalized joint hypermobility are major diagnostic criteria). 1, 14 This finding suggests that, at least for this cohort, the diagnosis of vEDS in the absence of confirmatory testing cannot be trusted. In the period that overlaps the time span for this study, gene discovery studies had identified more than a dozen genes associated with aneurysms and dissections. Some of those conditions overlap clinically with vEDS, such as other forms of EDS that result from mutations in COL5A1 and COL1A1. 1 Thus, although the major and minor diagnostic clinical criteria can be used to help to raise the suspicion for a vEDS, the diagnosis must be confirmed by genetic testing. In vEDS, the major diagnostic criteria have high diagnostic specificity. 1 Even when these diagnostic clinical criteria are present, molecular testing is essential to confirm the diagnosis. A confirmation of the diagnosis by molecular testing is critical for several reasons. Not only are there clinical features that overlap with the other subtypes of EDS, there are clinical features that overlap with other heritable connective tissues disorders and genetically triggered arteriopathies that result from mutations in the genes involved in the transforming growth factor-b signaling pathway, extracellular matrix production, and aortic smooth muscle cells development and function. 2, [15] [16] [17] [18] [19] Establishing the correct diagnosis has serious implications of lifelong surveillance, medical and surgical management recommendations, and pregnancy planning for the patient and family members. 2, 8 The diagnosis can be confirmed by obtaining a skin biopsy or by genetic testing for pathogenic variants in the COL3A1, but the latter is the contemporary approach to diagnosis. 2   Table II Because not all COL3A1 variants are pathogenic, the interpretation of the genetic testing results by an individual trained in variant assessment in keeping with the American College of Medical Genetics guidelines 3, 7, 12 is essential to establishing the diagnosis. We found that nearly 10% of individuals in whom at least some of the clinical criteria for vEDS were met had nonpathogenic COL3A1 variants and with current criteria did not have vEDS. This finding, too, has substantial implications for the individuals and their family members. An accurate diagnosis of vEDS has research implications. An example derives from the BBEST celiprolol trial, which aimed to assess if celiprolol (a long-acting b1-adrenergic receptor antagonist with partial b2-adrenergic receptor agonist) would decrease the risk of arterial dissections and ruptures in treated individuals. 20 In this trial, the 53 enrolled individuals had a diagnosis of vEDS made by clinical criteria alone and only 33 were found to have a pathogenic COL3A1 variant (52% in the celiprolol arm and 71% of the controls). The trial concluded that celiprolol decreased arterial rupture after extended treatment, based in part on the whole cohort. The presence of a misidentified disease process in those patients diagnosed by clinical criteria only suggests that the trial's experimental group was populated with patients at less (or more) risk for arterial events than the control group. Celiprolol is currently unavailable in the United States. Medical management in vEDS has been extrapolated from this study (use of b-blockers) as well as management of Marfan syndrome (use of atenolol and losartan) without additional trials in place. [20] [21] [22] A pragmatic trial to evaluate the role of anti-impulse therapy in patients with vEDS is still necessary to establish efficacy for celiprolol or other b-blockers.
In this study, a vEDS diagnosis was made at an earlier age in the setting of a family history of other family members with vEDS or a history of aortic or arterial aneurysms or dissections. This finding has been previously demonstrated 2 and highlights an opportunity for early diagnosis. 23 However, the family history is frequently absent, because 50% people in whom the diagnosis of vEDS is made have de novo mutations in COL3A1 and the patient is the first in their family to have the mutation. 3, 5 An additional window of opportunity for early diagnosis is at the time of presenting with a spontaneous pneumothorax, because this entity seems to present at a younger age with male predominance compared with individuals presenting with intestinal or arterial events, as demonstrated in this series and in a recent report on a separate cohort of patients with vEDS. 24 This study demonstrates the limits related to the use of a diagnostic code when it does not discriminate among different bases for a common disorder. All 13 types of EDS are included in a single diagnostic code in both the ICD-9 and the ICD-10 (Q79.6). This creates confusion among clinicians and individuals with limited experience with vEDS and prevents the use of administrative data sets the study of vEDS. As a result, there is a call for the creation of separate ICD codes for the different subtypes by the patient advocacy groups.
This study is limited by the relatively small numbers of cases. The syndrome is rare; thus, accruing large numbers for analysis is challenging even in multi-institutional study designs. By virtue of the study design, it was not possible to ascertain systematically how these individuals in this cohort came to clinical attention and as such, this cohort may not be representative of the entire vEDS population. In this cohort, over half of the individuals in this cohort had an arterial event and the median age of death (38.5 years) was younger than was has been previously reported (51 years). 7, 25 The younger death, in part, could be due to the identifications of individuals with a severe phenotype who are identified because of a complication. Additionally, owing to the rarity of vEDS, few clinicians have encountered affected individuals and, as such, this could lead to the under-recognition of the milder phenotypes. Despite these limitations, the study adds to our understanding of vEDS and the importance of accurate diagnosis.
CONCLUSIONS
This study highlights the importance of confirming vEDS diagnosis by testing for pathogenic COL3A1 variants rather than making the diagnosis by using clinical diagnostic criteria alone. This finding is highly relevant, because the clinical features of vEDS overlap with those of other forms of EDS and other genetically triggered arteriopathies. The interpretation of the testing results by an individual trained in variant assessment is essential to confirm the diagnosis given that not all variants of COL3A1 are pathogenic. Accurate diagnosis is critical and has serious implications for lifelong screening and treatment strategies for the affected individual and family members as well as for research to identify treatments, genetic modifiers, and outcomes.
